Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances
Language English Country Sweden Media print
Document type Journal Article
PubMed
30431741
PII: NEL390318A03
Knihovny.cz E-resources
- MeSH
- Autoimmune Diseases chemically induced MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized adverse effects MeSH
- Hydrocortisone deficiency MeSH
- Pituitary Gland diagnostic imaging MeSH
- Hypopituitarism chemically induced diagnostic imaging MeSH
- Ipilimumab adverse effects MeSH
- Colitis chemically induced MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphadenitis chemically induced MeSH
- Autoimmune Hypophysitis chemically induced diagnostic imaging MeSH
- Magnetic Resonance Imaging MeSH
- Melanoma drug therapy pathology MeSH
- Mesentery MeSH
- Skin Neoplasms drug therapy pathology MeSH
- Pancreatitis chemically induced MeSH
- Pneumonia chemically induced diagnostic imaging MeSH
- Tomography, X-Ray Computed MeSH
- Antineoplastic Agents, Immunological adverse effects MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antibodies, Monoclonal, Humanized MeSH
- Hydrocortisone MeSH
- Ipilimumab MeSH
- pembrolizumab MeSH Browser
- Antineoplastic Agents, Immunological MeSH
OBJECTIVES: Immune checkpoints inhibitors (ICI) represent a new therapy option for the treatment of several advanced tumors. However, this therapy has been linked to a spectrum of ICI related autoimmune (AI) adverse events. Some may be life threatening and their diagnosis is tricky. The aim of our study was to describe various imaging appearances of ICI related secondary hypophysitis and other coincidental AI diseases. MATERIAL AND METHODS: We included 28 patients (19 females, 9 men, mean aged 58±13 years), who were consecutively treated mostly for advanced stage melanoma by different ICI. All their CT/MRI records and clinical data were reviewed. RESULTS: We found 5 (18%) cases of endocrinology proven secondary hypophysitis; 2 cases of panhypopituitarism and 3 cases of central hypocortisolism. Four cases were MRI positive, 1 case was MRI negative. Three cases were accompanied by other AI diseases: 1 by hemorrhagic colitis and mesenterial lymphadenitis, 1 by AI pancreatitis and 1 by pneumonitis. On MRI pituitary gland was swollen in 3 cases, twice enhanced non-homogenously, once homogenously; infundibular enlargement was present in 2 cases. Those 3 cases reacted to glucocorticoid therapy by hypophyseal shrinkage. In 1 case of MRI positive hypophysitis, the pituitary gland was not enlarged, slightly nonhomogeneous with peripheral contour enhancement; no reaction to glucocorticoids was mentioned. CONCLUSION: Secondary hypophysitis is probably more common ICI related adverse event than reported in the literature. Its MRI appearance is variable. Most of our cases were in coincidence with other AI ICI related events that affected their clinical manifestations.